Name: Muramyl dipeptide (MDP)
Brand: Selleck Chemicals
SKU: S9709
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Purity: >97%

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS

97

Related Targets	CDK HSP PD-1/PD-L1 ROCK Wee1 DNA/RNA Synthesis Microtubule Associated Ras KRas Aurora Kinase
Other RUNX Inhibitors	CADD522 XRK3F2

Solubility

In vitro
Batch:

DMSO : 98 mg/mL (198.99 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 98 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.900mg/ml (9.95mM)	Taking the 1 mL working solution as an example, add 50 μL of 98 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.225mg/ml (2.49mM)	Taking the 1 mL working solution as an example, add 50 μL of 24.5 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	492.48	Formula	C₁₉H₃₂N₄O₁₁	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	53678-77-6	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Mechanism of Action

Targets/IC₅₀/Ki	Runx2
In vitro	Muramyl dipeptide (MDP) directly augments osteoblast differentiation and bone-forming gene expression by Runx2 activation. Despite no direct effect, it indirectly attenuates osteoclast differentiation through down-regulation of the RANKL/OPG ratio. This compound increases the expression of its receptor, Nod2, and MDP-induced bone formation and osteoblast activation does not occur during Nod2-deficiency.
In vivo	In mice administered with Muramyl dipeptide (MDP), increased bone and mineral density by enhanced bone formation are observed. Remarkably, pre-treatment or post-treatment with this compound alleviates bone loss in RANKL-induced osteoporosis mouse models.
References	[1] https://pubmed.ncbi.nlm.nih.gov/28337794/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06079567	Recruiting	Facioscapulohumeral Muscular Dystrophy Type 2	Centre Hospitalier Universitaire de Nice	October 3 2023	Not Applicable
NCT06045338	Not yet recruiting	Long COVID\|Post-Acute Sequelae of COVID-19\|COVID Long-Haul	Beth Israel Deaconess Medical Center	October 2023	Not Applicable
NCT06110403	Recruiting	Copd	University Hospital Lille\|AstraZeneca	September 29 2023	Phase 1\|Phase 2
NCT06012006	Not yet recruiting	COPD	Assistance Publique - Hôpitaux de Paris	August 2023	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Muramyl dipeptide (MDP) RUNX activator

Chemical Structure

Molecular Weight: 492.48